Back to top
more

Johnson & Johnson (JNJ)

(Delayed Data from NYSE)

$146.14 USD

146.14
6,182,473

-0.68 (-0.46%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $145.99 -0.15 (-0.10%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 20% (202 out of 252)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

What's in Store for Abbott Labs (ABT) This Earnings Season?

Abbott Laboratories (ABT) is scheduled to report fourth-quarter and full year 2016 results before the opening bell on Jan 25.

    Abbvie (ABBV) Imbruvica Approved in Lymphoma Indication

    AbbVie Inc. (ABBV) announced that the FDA has approved its blood cancer drug, Imbruvica, for the treatment of patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL).

      What???s Ahead for Johnson & Johnson (JNJ) in Q4 Earnings?

      Johnson & Johnson (JNJ), the bellwether of healthcare companies, is scheduled to report fourth-quarter 2016 and full-year results on Jan 24.

        Madeleine Johnson headshot

        Stock Market Roundup Jan. 11: Health Sector Lower on Trump "Murder" Comment

        After President-elect Donald Trump said pharmaceutical companies were ???getting away with murder,??? in how much they charge the government for medicines.

          Novo Nordisk (NVO) Fiasp Gets EU Nod for Diabetes in Adults

          Novo Nordisk (NVO) announced that its fast-acting insulin aspart, Fiasp, has been approved in the EU for the treatment of diabetes in adults.

            Neena Mishra headshot

            5 ETF Investment Ideas for 2017

            We have highlighted some ETF areas that are likely to shine in 2017.

              Bristol-Myers, GeneCentric Tie Up for Opdivo Biomarker Study

              Bristol-Myers (BMY) and GeneCentric Diagnostics inked an exploratory biomarker research collaboration.

                Pfizer's Humira Biosimilar Meets Primary Endpoint in Study (Revised)

                Pfizer, Inc. (PFE) announced positive top-line results from the comparative REFLECTIONS B538-02 study on its investigational compound, PF-06410293, a potential biosimilar to AbbVie Inc.'s (ABBV) Humira.

                  The Zacks Analyst Blog Highlights: Johnson & Johnson, Barclays, Procter & Gamble, Kellogg and Medtronic

                  The Zacks Analyst Blog Highlights: Johnson & Johnson, Barclays, Procter & Gamble, Kellogg and Medtronic

                    Pfizer's Humira Biosimilar Meets Primary Endpoint in Study

                    Pfizer, Inc. (PFE) announced positive top-line results from the comparative REFLECTIONS B538-02 study on its investigational compound, PF-06410293, a potential biosimilar of Humira approved for the treatment of patients with rheumatoid arthritis.

                      Bristol-Myers, J&J Ink Immunotherapy Research Collaboration

                      Bristol-Myers (BMY) entered into an immunotherapy clinical research collaboration with Johnson & Johnson to evaluate a combination of Opdivo and Darzalex.

                        Lilly Jardiance Family Diabetes Drugs' Label to be Updated

                        Eli Lilly & Company (LLY) recently announced that the FDA has approved the inclusion of data from the EMPA-REG OUTCOME study on the labels of three type 2 diabetes medicines belonging to the Jardiance family ??? Synjardy, Synjardy XR and Glyxambi.

                          Company News for January 03, 2017

                          Companies In The News are: MYL,JNJ,GPOR,PBR,S,TMUS

                            Mylan (MYL) Announces Multiple Generic Launches in the U.S.

                            Mylan (MYL) announced quite a few generic launches in the U.S. in Dec 2016.

                              Achillion Receives $15M from J&J for HCV Study Enrolment

                              Achillion Pharmaceuticals, Inc. (ACHN) announced that it has received a milestone payment of $15 million from Johnson & Johnson's (JNJ) pharma wing, Janssen for the initiation of patient enrollment in the OMEGA-1 phase IIb global study of JNJ-4178.

                                Anthera (ANTH) Stock Falls on Poor Phase III Sollpura Data

                                Anthera (ANTH) reported unimpressive top-line data from a phase III study on Sollpura in cystic fibrosis patients with exocrine pancreatic insufficiency.

                                  Ionis Receives $5 Million Milestone from J&J Unit for GI Drug

                                  Ionis Pharmaceuticals, Inc. (IONS) announced that it has earned $5 million milestone payment from Janssen Biotech, Inc., a pharmaceutical division of Johnson & Johnson (JNJ).

                                    J&J Resumes Talks with Actelion: Did Sanofi Just Lose Out?

                                    In an interesting turn of events, Johnson & Johnson (JNJ) announced that it is once again discussing a possible transaction with Swiss biotechnology company Actelion Ltd. (ALIOF).

                                      J&J Files for FDA Approval of Simponi Aria Label Expansion

                                      Johnson & Johnson's (JNJ), Janssen submitted two sBLAs in the U.S. seeking approval of Simponi Aria for the treatment of psoriatic arthritis and ankylosing spondylitis.

                                        Big Pharma Face Off: Is Merck More Attractive than J&J?

                                        Johnson & Johnson (JNJ) and Merck & Co. Inc. (MRK) are some of the better-performing large-cap pharma stocks

                                          Company News for December 15, 2016

                                          Companies In The News are: ABM,JNJ,ALIOF,HTZ,VRX

                                            Pfizer: FDA Approves Eczema Ointment; Xtandi Fails Study

                                            Pfizer, Inc. (PFE) announced that it received FDA approval for crisaborole topical ointment to treat mild-to-moderate eczema, or atopic dermatitis, in patients two years and older. The ointment will be sold under the brand name Eucrisa.

                                              J&J (JNJ) Ends Deal Talks with Actelion: Will Sanofi Gain?

                                              On Tuesday, Johnson & Johnson (JNJ) announced that it has ended talks regarding a possible transaction with Swiss biotechnology company, Actelion Ltd. (ALIOF), reportedly for a disagreement over the purchase price.

                                                Lilly (LLY) Gets FDA Nod for Once-Daily Version of Synjardy

                                                Eli Lilly and Company (LLY) announced the FDA approval of an extended-release formulation of its type II diabetes prescription drug Synjardy.

                                                  Swarup Gupta headshot

                                                  3 Stocks That Propelled the Dow to a Fresh All-Time High

                                                  Analyzing the reasons behind these gains could help us in ascertaining whether they are sustainable.